Transplant/Artificial Liver
Liver Transplant - HBV
Increased Distance Reduces Likelihood of Liver Transplant
- Details
- Category: Liver Transplant - HBV
- Published on Friday, 04 April 2014 00:00
- Written by Liz Highleyman
Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.
Human Stem Cells Used to Create Functional Liver Cells in Mice
- Details
- Category: Liver Transplant - HBV
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
Researchers have discovered a way to generate functional hepatocytes (liver cells) from human stem cells, which worked as expected and increased survival when transplanted into mice with acute liver injury, researchers reported in the July 9, 2013, advance online edition of Stem Cells and Development.
Hepatitis B Patients with HBeAg Seroconversion on Treatment May Not Have Durable Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Liz Highleyman
People with chronic hepatitis B virus (HBV) who achieve hepatitis B "e" antigen (HBeAg) seroconversion when treated with nucleoside/nucleotide analogs are more likely to experience HBeAg seroreversion and HBV reactivation than those with natural clearance, according to a study described in the November 15, 2012, Journal of Infectious Diseases.
Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection
- Details
- Category: Liver Transplant - HBV
- Published on Wednesday, 20 February 2013 00:00
- Written by Novartis
The U.S. Food and Drug Administration (FDA) this month approved the immunosuppressant drug everolimus (brand name Zortress) for preventing organ rejection in people who undergo liver transplantation. A recent large study found that everolimus was easier on the kidneys when used in combination with low-dose tacrolimus (Prograf).
Entecavir (Baraclude) Label Adds Data on Black Patients and Liver Transplant Recipients with HBV
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 16 October 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration this week approved revised product information for entecavir (Baraclude) for the treatment of chronic hepatitis B virus (HBV) infection, adding new data from studies of African-American patients -- showing no differences in pharmacokinetics or safety -- and of people who received liver transplants. 
More Articles...
- Researchers Grow Liver Tissue from Pluripotent Stem Cells
- Changes Proposed for Allocation of Donated Livers
- Artificial Liver Device Improves Survival for Hepatitis B and C Patients with Decompensated Disease
- EASL 2010: MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival
Web Design and Development by